Development of a Humanized IL33 Mouse
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
PROJECT SUMMARY: In this R03 application, “Development of a Humanized IL33 Mouse” we plan to engineer and characterize a mouse strain in which the human IL33 gene sequence from ~28 kb (including the 20 kb asthma-associated region) upstream of exon 1 to ~21 kb downstream of exon 8 of human IL33 gene will be cloned into intron 1 of ROSA26 locus in the mouse. This strategy uses a bacterial artificial chromosome (BAC) to insert all of the human regulatory regions which have been associated with allergic disease into the mouse. The targeting strategy uses the PiggyBac technology to deliver a single copy of the transgene into the specific integration site. The strategy includes the upstream regulatory regions because they confer localization of the human IL33 gene expression to the bronchial epithelial cells and the endothelium. That is in contrast to the mouse Il33 gene expression which is located in the lung type 2 alveolar epithelial cell. The mouse will also have lox-p sites introduced into exon 5 which can be used to conditionally delete IL33 expression. Finally, the human IL33 locus will drive an IRES-Citrine reporter that can report on the expression of the human IL33 promoter. This mouse will be crossed to the Il33cherry mouse which is a knock-in/knock-out (mcherry reporter) so that the resulting mouse will only have human IL-33 protein (which is biologically active in mice) from the human IL33 promoter along with a human IL33 Citrine reporter and a mouse Il33 cherry reporter. This mouse will then be compared to wildtype mice in an acute lung allergen challenge model to determine how localization of expression to different lung cell types (bronchial epithelium/endothelium vs type 2 alveolar epithelium) alters the location of lung type 2 infiltrates and the degree of bronchial epithelial remodeling. This proposal will utilize novel spatial transcriptomic technologies to ask important questions about how IL-33 localization alters the architecture of lung type 2 inflammation. This mouse has great potential to advance our understanding of human genetics since the asthma-associated genetic architecture (upstream of the human IL33 gene) will be introduced into the mouse.
Grant Summary
Development of a Humanized IL33 Mouse is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $175K for university, nonprofit, healthcare org. Applications are due 2028-03-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $175K
2028-03-31
- 1Confirm your organization is eligible for Development of a Humanized IL33 Mouse from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Development of a Humanized IL33 Mouse: Frequently Asked Questions
Who is eligible for the Development of a Humanized IL33 Mouse?
Development of a Humanized IL33 Mouse is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Development of a Humanized IL33 Mouse provide?
Development of a Humanized IL33 Mouse provides up to $175K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Development of a Humanized IL33 Mouse deadline?
Applications for Development of a Humanized IL33 Mouse are due 2028-03-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Development of a Humanized IL33 Mouse?
To apply for Development of a Humanized IL33 Mouse, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.